Sign In

Friday, October 04, 2019 - 8:00 am to Saturday, October 05, 2019 - 2:00 pm
Add to Calendar

Registration, housing and abstract submission will open Wednesday, June 12 at 9:00 am ET.

Course Description / Needs Statement

Leading experts in the field of alcoholic liver disease (ALD) research and therapy will explore multiple aspects of managing patients. The Improving Outcomes in Alcohol-associated Liver Disease Through Robust Basic and Translational Research meeting will bridge critical gaps in ALD diagnosis, management and clinical trial design. Speakers will present evidence-based knowledge on ALD’s potential triggers, the role of alcohol dependence in management, various stages of disease, gender differences, and potential biomarkers for diagnosis, disease severity and prognosis. The program will include practical guidance on ways to create effective multidisciplinary teams to manage ALD patients, where hepatologists, addiction specialists, social workers, nurses and a patient’s family members work together as a team.

Program Chairs

  • Michael Lucey, MD, FAASLD
  • Philippe Mathurin, MD, PhD
  • Gyongyi Szabo, MD, PhD, FAASLD
  • Mark Thursz, MD

Scientific Program Advisor

  • Vijay Shah, MD, FAASLD

Location

  • Renaissance Chicago Downtown Hotel
    1 W. Wacker Drive
    Chicago, IL 60601
    Phone: 312-372-7200

Learning Objectives

At the conclusion of this activity, participants will be able to:

  • Define the various stages and presentations of alcoholic liver disease and alcoholic hepatitis.
  • Present improved management and treatment options to patients with ALD based on expert recommendations.
  • Review challenges in clinical trial design, patient enrollment and outcomes in ALD.

Continuing Education

Continuing education will not be provided for this conference.

Travel Note

US residents: Please review the Real ID Act regarding boarding federally regulated commercial aircrafts. Depending on your state of residence, you may need to provide a second form of identification at the airport.

Schedule Note

Breakfast is served at 7 am ET both days.

Registration Pricing Early Bird: On or Before September 3

  • Member $325
  • Trainee & Assoc. Members $185
  • Non-Member $540
    Any physician, scientist, or researcher with doctoral-level training
    who is not employed by Industry (pharma/device/etc.)
  • Trainee & Assoc. Non-Member $235
    Any physician, scientist or researcher in a training program as certified
    by the director of their training program. This category also includes, but is not limited to, the degrees of MS, NP, PA, RN, and other related or comparable degrees.
  • Industry $775
    Any Industry (pharma/device/etc.) employee with or without medical training.
  • Student $90
  • Student Non-Member $115

Registration Pricing: On or After September 4

  • Member $425
  • Trainee & Assoc. Members $210
  • Non-Member $640
    Any physician, scientist, or researcher with doctoral-level training
    who is not employed by Industry (pharma/device/etc.)
  • Trainee & Assoc. Non-Member $260
    Any physician, scientist or researcher in a training program as certified
    by the director of their training program. This category also includes, but is not limited to, the degrees of MS, NP, PA, RN, and other related or comparable degrees.
  • Industry $875
    Any Industry (pharma/device/etc.) employee with or without medical training.
  • Student $105
  • Student Non-Member $130

Registration Cancellation Policy

Requests for cancellations must be submitted in writing to meetings@aasld.org.

Cancellations received on or before September 3, 2019 will be eligible for a full refund.

Cancellations received between September 4 – September 17, 2019 will be subject to a $50.00 cancellation fee.

Cancellations received on or after September 18, 2019 are not eligible for a refund.

Friday, October 4 -- Session I: Recalibrating the Clinical Phenotype of AALD

Moderators: Gyongyi Szabo, MD, PhD, FAASLD and Giovanni Addolorato, MD

  • 8:00 am – 8:20 am
    Epidemiology of AALD
    Suthat Lianpunsakul, MD, MPH, FAASLD
  • 8:20 am – 8:40 am
    Moderate Alcoholic Hepatitis: What is it, and How Should it Be Studied?
    Ramon Bataller, MD, PhD
  • 8:40 am – 9:00 am
    Alcohol-associated Fibrosis and Cirrhosis: Clinical Research Opportunities and Needs in this Patient Population
    Mack C. Mitchell, MD, FAASLD
  • 9:00 am – 9:20 am
    NASH-AALD Overlap Syndromes
    Quentin M. Anstee, MBBS, PhD, FRCP
  • 9:20 am – 9:40 am
    Q&A
  • 9:40 am – 10:10 am
    Break

Friday, October 4 -- Session II: Translational Science and Application of Preclinical Targets to Clinic in AALD

Moderators: Vijay Shah, MD, FAASLD and Alexandre Louvet, MD

  • 10:10 am – 10:30 am
    Key Features of the Patho-mechanisms of AALD and Alcoholic Hepatitis Including Gut-liver Axis and the Microbiome
    Gyongyi Szabo, MD, PhD, FAASLD
  • 10:30 am – 10:50 am
    Bile Acids - FGF19 and Cholestasis, Liver Regeneration, and Biologic Targets
    Bernd Schnabl, MD
  • 10:50 am – 11:10 am
    Impact of Infection on Progression of AALD: Mechanisms of Susceptibility and Management, Immunosuppression, and Biomarkers of Infection
    Nikhil Vergis, MRCP
  • 11:10 am – 11:30 am
    ACLF Specificity in ALD
    Christophe Moreno, MD, PhD
  • 11:30 am – 12:00 pm
    Q&A
  • 12:00 pm – 1:00 pm
    Lunch

Friday, October 4 -- Session III: Alcohol Use Disorder -- Considerations for Inclusion in Clinical Trials

Moderators: Mark Thursz, MD and Jessica L. Mellinger, MD

  • 1:00 pm – 1:20 pm
    Natural History of Alcohol Use Disorder and Psychological Health of Patients AUD: How Psychological Co-morbidities Interact with AUD
    Thomas P. Beresford, MD
  • 1:20 pm – 1:40 pm
    Treating Patients with Alcohol Use Disorder: Lessons for the Hepatology Community from the Addiction Medicine and Integrating AUD Treatment into the Care of Liver Disease Patients
    Giovanni Addolorato, MD
  • 1:40 pm – 2:00 pm
    Use of Validated Questionnaires and Biomarkers to Monitor Alcohol Use in Clinical Trials
    Lorenzo Leggio, MD, PhD, MSc
  • 2:00 pm – 2:20 pm
    Clinical Trial Design: Endpoints for AUD in Liver Patients
    Jessica L. Mellinger, MD
  • 2:20 pm – 2:40 pm
    Q&A
  • 2:40 pm – 3:00 pm
    Break

Friday, October 4 -- Session IV: Liver Transplantation for AALD

Moderators: Michael Lucey, MD, FAASLD and Christophe Moreno, MD, PhD

  • 3:00 pm – 3:20 pm
    Current Landscape in Liver Transplantation in the US and Europe: Selection Criteria and Social Factors
    Michael R. Lucey, MD, FAASLD
  • 3:20 pm – 3:40 pm
    Relapse of Alcohol After Liver Transplantation
    Georges-Philippe Pageaux, MD, PhD
  • 3:40 pm – 4:00 pm
    Debate on Selection Criteria for Liver Transplantation for AALD: Liberalize Criteria
    Gene Y. Im, MD
  • 4:00 pm – 4:20 pm
    Debate on Selection Criteria for Liver Transplantation For AALD: Restrict Criteria
    James Neuberger, MD, FAASLD
  • 4:20 pm – 4:40 pm
    Liver Transplantation for AALD: How Can We Construct Robust Clinical Studies
    Norah Terrault, MD, MPH, FAASLD
  • 4:40 pm – 5:00 pm
    Current Landscape in Clinical Trials and Evolving Targets
    Vijay Shah, MD, FAASLD
  • 5:00 pm – 5:15 pm
    Q&A
  • 5:15 pm – 6:30 pm
    Group Discussions
    1. Which biologic targets offer the best hope for clinical study?
    2. Use of biomarkers in clinical studies?
    3. Monitoring for, and analyzing for the impact of return to alcohol use in the longer-term studies.
    4. Optimizing end-points for phase I, II and III studies, and how should surrogate alternatives to mortality be adopted in the short-term.
    5. Creating a consensus around criteria for selection for liver transplantation of AALD patients with short duration of abstinence.
  • 6:30 pm – 7:30 pm
    Poster Reception

Saturday, October 5 -- Session V: Clinical Trials: How Far Have We Advanced Since the First Joint Meeting?

Moderators: Philippe Mathurin, MD, PhD and Veronica Pei, MD, MEd, MPH

  • 8:00 am – 8:20 am
    Severe AH: Future Studies in Phase I & II Clinical Trials: Endpoints, Duration, Monitoring Alcohol Relapse, Use of Surrogate Endpoints, Including Biomarkers
    Philippe Mathurin, MD, PhD
  • 8:20 am – 8:40 am
    Severe AH: Future Phase III Studies: End-points, Duration, Monitoring Alcohol Relapse, Use of Surrogate Endpoints, Including Biomarkers
    Mark Thursz, MD
  • 8:40 am – 9:00 am
    Moderate AH: Challenges to Clinical Trials in AALD: Recruiting Subjects to Meet Power Assessments, End-points, Duration, Monitoring Alcohol Relapse, Endpoints, Use of Surrogate Endpoints, Including Biomarkers
    Alexandre Louvet, MD
  • 9:00 am – 9:20 am
    Alcoholic Cirrhosis: Challenges to Clinical Trials in AALD: Recruiting Subjects to Meet Power Assessments, End-points, Duration, Monitoring Alcohol Relapse, Endpoints, Use of Surrogate Endpoints, Including Biomarkers
    Timothy R. Morgan, MD, FAASLD
  • 9:20 am – 9:40 am
    Studies of Natural History to Develop Virtual Placebo Controls
    Veronica Pei, MD, MEd, MPH
  • 9:40 am – 9:55 am
    Q&A
  • 9:55 am – 10:05 am
    Break

Saturday, October 5 -- Session VI: Special Considerations in AALD Clinical Trials

Moderators: Gyongyi Szabo, MD, PhD, FAASLD and Shiv K. Sarin, MD, FAASLD

  • 10:05 am – 10:25 am
    AALD in Women
    Marsha Morgan, MD
  • 10:25 am – 10:45 am
    Nutrition in AALD
    Craig J. McClain, MD, FAASLD
  • 10:45 am – 11:05 am
    Liver Regeneration in AALD
    Bin Gao, MD, PhD
  • 11:05 am – 11:25 am
    Special Considerations and Opportunities in AALD Clinical Trials in Countries of APASL
    Shiv K. Sarin, MD, FAASLD
  • 11:25 am – 11:45 pm
    Special Considerations and Opportunities in AALD Clinical Trials in Countries of ALEH
    Juan P. Arab, MD
  • 11:45 am – 12:05 pm
    Q&A
  • 12:05 pm – 12:15 pm
    Closing Remarks
    Gyongyi Szabo, MD, PhD, FAASLD